sure the vaccines we have to stay ahead of the curve and we don tjust keep buying lots and lots and lots of vaccine against wuhan when actually we need to start thinking about what these new variants look like. if that means three doses, thatis like. if that means three doses, that is what we need to do now but that is what we need to do now but thatis that is what we need to do now but that is not adequate going forward. if you look at the public accounts committee report, the cost of deployment last year when i was in post was about the same as the cost of buying the vaccines we bought last year, so we cannot be in a position where we have to go through this monumental logistics challenge of getting vaccines into arms, so the other area we must push forward is how do we improve the format of these vaccine so they are much easier and cheaper to deploy? whether that is patches, sprays, whatever, we need to find the
the tent who know exactly what is happening, but if i was glad now, i would be absolutely focusing my attention is under energies on the advancement and manufacturing and skills and process development capability and notjust on procurement. capability and not ust on procurement. capability and not ust on procurement. capability and not ust on rocurement. ., ,, , ., ., ., procurement. thank you. how worried which ou procurement. thank you. how worried which you have procurement. thank you. how worried which you have been procurement. thank you. how worried which you have been about procurement. thank you. how worried which you have been about omicron i which you have been about omicron were you which you have been about omicron were you still reading the vaccine task for were you still reading the vaccine task for the? of were you still reading the vaccine task for the? were you still reading the vaccine task for the? , , , . task for the? of course we expected variants.
speed was the right instruction and i think that is correct, but we have to be nimble in how quickly we can manufacture these variance vaccines because i think we will have to produce the variants. because i think we will have to produce the variants. thank you very much. produce the variants. thank you very much- carol? produce the variants. thank you very much. carol? studio: produce the variants. thank you very much. carol? studio: that- produce the variants. thank you very much. carol? studio: that is- much. carol? studio: that is dame kate bingham, former chair of the vaccines have force, talking to members of the science and technology committee in the house of commons, looking up a new omicron variants amongst a broader discussion about how to deal with new variants. kate bingham discussing manufacturing, procurement and deployment of vaccines. she said the big question is how we can make sure vaccines stay ahead of the curve as new variants emerge. one of the key tools in
deployed in a timely manner? the answer is l deployed in a timely manner? tie: answer is i don t know in detail, i know when i left clive edicts put together a pretty comprehensive variant manufacturing plan which was really good which looks ahead and figures out what are the potential variance, testing them against the vaccines we have because it is important to scale up the industrialised testing to do exactly this, and if those vaccines do not work, go ahead and start making tweaked variants before those variants potentially emerge. i know there was a plan, i don t know to what extent it is being followed. thank you very much, rebecca, i will go tojeremy hunt. t thank you very much, rebecca, i will go to jeremy hunt- go to jeremy hunt. i would like to follow one go to jeremy hunt. i would like to follow one from go to jeremy hunt. i would like to follow one from rebecca s - go to jeremy hunt. i would like to i follow one from rebecca s question, dame follow one from rebecca
partner was to have that capability to grow up variance vaccines. it is not trivial and not every virus can be grown, but that is one of the ideas of how would you get ahead of the mutations of the vaccine. it may be it has been done, i certainly read in the press that different vaccine companies are creating omicron variants but that is what i think we should be doing both historically and what we should do in the future is predicting what they will be at making vaccines accordingly. the testing, we have the capability to test head how effective the vaccines are against these. ourfocus last effective the vaccines are against these. our focus last year was very much on speed, it was not about getting the perfect vaccine. what has become clear is the rate of mutation here is quite rapid so